➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Medtronic
AstraZeneca
Boehringer Ingelheim
Dow

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GUANFACINE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Guanfacine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004376 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder Completed Yale University Phase 3 1994-09-01 OBJECTIVES: I. Evaluate the safety and efficacy of the alpha-2 adrenergic agonist guanfacine in children and adolescents with Tourette syndrome or other chronic tic disorder, and attention deficit hyperactivity disorder.
NCT00004376 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder Completed National Center for Research Resources (NCRR) Phase 3 1994-09-01 OBJECTIVES: I. Evaluate the safety and efficacy of the alpha-2 adrenergic agonist guanfacine in children and adolescents with Tourette syndrome or other chronic tic disorder, and attention deficit hyperactivity disorder.
NCT00007592 Hypertension Screening and Treatment Program Completed VA Office of Research and Development N/A 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00018603 Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD) Completed VA Office of Research and Development Phase 1 1999-11-01 This is a double-blind, placebo-controlled, randomized study lasting 8 weeks. Purpose of the study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and second, to explore neurobiological mechanisms of action of guanfacine.
NCT00025779 Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders Completed National Institute of Mental Health (NIMH) N/A 2001-10-01 This study will evaluate the efficacy and safety of methylphenidate for treating hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Data supporting its safety and effectiveness in treating ADHD symptoms in PDD are limited. Children and adolescents who do not show a positive response to methylphenidate will be invited to participate in a pilot study of the non-stimulant medication guanfacine (Tenex).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Guanfacine Hydrochloride

Condition Name

Condition Name for Guanfacine Hydrochloride
Intervention Trials
Attention Deficit Hyperactivity Disorder 6
Attention-deficit/Hyperactivity Disorder 5
Attention Deficit Disorder With Hyperactivity 5
Hypertension 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Guanfacine Hydrochloride
Intervention Trials
Attention Deficit Disorder with Hyperactivity 23
Disease 18
Hyperkinesis 17
Hypertension 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Guanfacine Hydrochloride

Trials by Country

Trials by Country for Guanfacine Hydrochloride
Location Trials
United States 217
United Kingdom 13
Spain 12
Germany 11
France 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Guanfacine Hydrochloride
Location Trials
Connecticut 17
New York 15
California 11
Tennessee 10
Florida 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Guanfacine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Guanfacine Hydrochloride
Clinical Trial Phase Trials
Phase 4 19
Phase 3 11
Phase 2 14
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Guanfacine Hydrochloride
Clinical Trial Phase Trials
Completed 30
Not yet recruiting 11
Recruiting 11
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Guanfacine Hydrochloride

Sponsor Name

Sponsor Name for Guanfacine Hydrochloride
Sponsor Trials
Shire 21
Yale University 17
National Institute on Drug Abuse (NIDA) 8
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Guanfacine Hydrochloride
Sponsor Trials
Other 63
Industry 24
NIH 20
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Express Scripts
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.